PL3687513T3 - Leczenie zespołu łamliwego chromosomu x i autyzmu z użyciem kannabidiolu - Google Patents

Leczenie zespołu łamliwego chromosomu x i autyzmu z użyciem kannabidiolu

Info

Publication number
PL3687513T3
PL3687513T3 PL18788905T PL18788905T PL3687513T3 PL 3687513 T3 PL3687513 T3 PL 3687513T3 PL 18788905 T PL18788905 T PL 18788905T PL 18788905 T PL18788905 T PL 18788905T PL 3687513 T3 PL3687513 T3 PL 3687513T3
Authority
PL
Poland
Prior art keywords
chromosom
cannabidiol
breakable
treatment
autism syndrome
Prior art date
Application number
PL18788905T
Other languages
English (en)
Inventor
Marcel Bonn-Miller
Nancy TICH
Donna Gutterman
John MESSENHEIMER
Terri Sebree
Original Assignee
Zynerba Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals, Inc. filed Critical Zynerba Pharmaceuticals, Inc.
Publication of PL3687513T3 publication Critical patent/PL3687513T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL18788905T 2017-09-28 2018-09-27 Leczenie zespołu łamliwego chromosomu x i autyzmu z użyciem kannabidiolu PL3687513T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762564834P 2017-09-28 2017-09-28
US201862632532P 2018-02-20 2018-02-20
PCT/IB2018/057519 WO2019064234A1 (en) 2017-09-28 2018-09-27 TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
EP18788905.0A EP3687513B1 (en) 2017-09-28 2018-09-27 Treatment of fragile x syndrome and autism with cannabidiol

Publications (1)

Publication Number Publication Date
PL3687513T3 true PL3687513T3 (pl) 2022-04-19

Family

ID=63878731

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18788905T PL3687513T3 (pl) 2017-09-28 2018-09-27 Leczenie zespołu łamliwego chromosomu x i autyzmu z użyciem kannabidiolu

Country Status (22)

Country Link
US (13) US10213390B1 (pl)
EP (3) EP3687513B1 (pl)
JP (5) JP7210564B2 (pl)
KR (2) KR102786277B1 (pl)
AU (2) AU2018343256B2 (pl)
BR (1) BR112020005918A2 (pl)
CA (2) CA3077330A1 (pl)
CY (1) CY1125071T1 (pl)
DK (1) DK3687513T3 (pl)
ES (2) ES2992838T3 (pl)
HR (1) HRP20220277T1 (pl)
HU (1) HUE058102T2 (pl)
IL (1) IL273495A (pl)
JO (1) JOP20200082B1 (pl)
LT (1) LT3687513T (pl)
MX (2) MX2020003606A (pl)
PL (1) PL3687513T3 (pl)
PT (1) PT3687513T (pl)
RS (1) RS62969B1 (pl)
SI (1) SI3687513T1 (pl)
SM (1) SMT202200093T1 (pl)
WO (1) WO2019064234A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
MX2020003606A (es) * 2017-09-28 2020-10-28 Zynerba Pharmaceuticals Inc Tratamiento del sindrome del cromosoma x fragil con canabidiol.
MX2021007076A (es) 2018-12-14 2021-08-11 Zynerba Pharmaceuticals Inc Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
EP4706647A3 (en) * 2019-09-17 2026-05-20 Harmony Biosciences Man Inc SYNGAP1 ENCEPHALOPATHY TREATMENT
EP4037663A1 (en) 2019-10-03 2022-08-10 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
GB2589306A (en) * 2019-10-25 2021-06-02 Gw Res Ltd Use of cannabidiol preparations in the treatment of fragile X syndrome
WO2021158059A1 (ko) 2020-02-07 2021-08-12 건국대학교 글로컬산학협력단 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
KR20230016003A (ko) * 2020-05-26 2023-01-31 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 자폐 스펙트럼 장애의 치료
IL299399A (en) * 2020-06-29 2023-02-01 Zynerba Pharmaceuticals Inc Treatment of fragile X syndrome with cannabidiol
MX2023006551A (es) * 2020-12-03 2023-08-17 Zynerba Pharmaceuticals Inc Tratamiento de las convulsiones refractarias.
CN116782891A (zh) * 2020-12-03 2023-09-19 Zyne制药公司 大麻二酚对难治性癫痫发作的治疗
AU2022373753A1 (en) * 2021-10-22 2024-05-09 Harmony Biosciences Management, Inc. Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
FI111733B (fi) 2002-02-20 2003-09-15 Pedipharm Oy Uudet metyloidut syklodekstriinikompleksit
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20080139472A1 (en) * 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
ES2534900T3 (es) 2007-07-30 2015-04-30 Zynerba Pharmaceuticals, Inc. Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
CA2772634C (en) 2009-08-31 2017-11-21 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
EP2943463B1 (en) 2013-01-08 2021-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Fluorinated cbd compounds, compositions and uses thereof
AU2014340709B2 (en) 2013-10-29 2019-07-04 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US20160022627A2 (en) 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
EP3160451B1 (en) 2014-06-27 2021-04-07 Farm To Farma, Inc. Buccal and sublingual cannabinoid formulations and method of making the same
WO2016004121A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CA3135893C (en) 2014-10-21 2023-11-14 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
WO2016109624A1 (en) 2014-12-30 2016-07-07 University Of Houston System Pharmaceutical compositions
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
WO2017068349A1 (en) 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
WO2017151980A1 (en) 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
EP3423047A4 (en) 2016-03-04 2020-01-01 Sharon Anavi-Goffer COMPOSITIONS OF CB2 RECEPTOR SELECTIVE AGONISTS FOR THE TREATMENT OF MENTAL DISEASES
PT3429580T (pt) 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
GB2549277B (en) 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
GB2549278B (en) 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
IL262419B2 (en) 2016-04-19 2024-08-01 Canna B Cure Ltd Cannabis-enriched enzymatically treated therapeutic composition
EP3478270A4 (en) 2016-06-02 2019-11-27 Acerus Labs, Inc. HALF-RESISTANT AND VISCOUS LIQUID, NADAL FORMULATIONS OF CANNABINOIDS
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN107126411A (zh) * 2017-03-22 2017-09-05 哈尔滨惠美佳生物科技有限公司 具有缓解神经性头痛作用的大麻二酚凝胶及其制备方法
WO2019034985A1 (en) 2017-08-14 2019-02-21 Zynerba Pharmaceuticals, Inc. METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL
SG11202002169TA (en) 2017-09-15 2020-04-29 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
MX2020003606A (es) 2017-09-28 2020-10-28 Zynerba Pharmaceuticals Inc Tratamiento del sindrome del cromosoma x fragil con canabidiol.
EP3703672A4 (en) 2017-10-30 2021-12-01 Endocanna Health, Inc. CANNABINOID FORMULATIONS
JP2021525709A (ja) 2018-05-24 2021-09-27 ティーオー ファーマスーティカルズ リミテッド ライアビリティー カンパニーＴＯ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＬＬＣ 自閉症スペクトラム障害の治療のためのカンナビスベースの組成物
US20230000793A1 (en) 2018-12-14 2023-01-05 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US20230000792A1 (en) 2018-12-14 2023-01-05 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
MX2021007076A (es) 2018-12-14 2021-08-11 Zynerba Pharmaceuticals Inc Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
KR20230016003A (ko) 2020-05-26 2023-01-31 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 자폐 스펙트럼 장애의 치료
IL299399A (en) 2020-06-29 2023-02-01 Zynerba Pharmaceuticals Inc Treatment of fragile X syndrome with cannabidiol
GB2597322A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
AU2022373753A1 (en) 2021-10-22 2024-05-09 Harmony Biosciences Management, Inc. Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Also Published As

Publication number Publication date
JP2023040166A (ja) 2023-03-22
US20250134832A1 (en) 2025-05-01
EP3687513B1 (en) 2021-12-15
JP2025061375A (ja) 2025-04-10
MX2022012424A (es) 2022-11-30
US20230414533A1 (en) 2023-12-28
US20200214995A1 (en) 2020-07-09
US11458110B2 (en) 2022-10-04
AU2024220039A1 (en) 2024-10-17
EP3687513A1 (en) 2020-08-05
SI3687513T1 (sl) 2022-04-29
JOP20200082B1 (ar) 2024-12-22
US20190167605A1 (en) 2019-06-06
EP4414030A2 (en) 2024-08-14
US10213390B1 (en) 2019-02-26
JP2022064988A (ja) 2022-04-26
US11779549B2 (en) 2023-10-10
ES2907325T3 (es) 2022-04-22
US20200360299A1 (en) 2020-11-19
KR102786277B1 (ko) 2025-03-26
MX2020003606A (es) 2020-10-28
HRP20220277T1 (hr) 2022-05-13
US12226373B2 (en) 2025-02-18
US20190117588A1 (en) 2019-04-25
US20200030255A1 (en) 2020-01-30
CA3077330A1 (en) 2019-04-04
LT3687513T (lt) 2022-03-10
KR20200058513A (ko) 2020-05-27
ES2992838T3 (en) 2024-12-18
US10471022B2 (en) 2019-11-12
JP7210564B2 (ja) 2023-01-23
JP2025106310A (ja) 2025-07-15
IL273495A (en) 2020-05-31
US20190262280A1 (en) 2019-08-29
US20220096396A1 (en) 2022-03-31
KR20220045070A (ko) 2022-04-12
DK3687513T3 (da) 2022-03-07
BR112020005918A2 (pt) 2020-10-06
US10568848B2 (en) 2020-02-25
EP4414030A3 (en) 2024-11-20
US10314792B2 (en) 2019-06-11
RS62969B1 (sr) 2022-03-31
US20230000790A1 (en) 2023-01-05
US20250134833A1 (en) 2025-05-01
US12213951B2 (en) 2025-02-04
CY1125071T1 (el) 2023-06-09
JOP20200082A1 (ar) 2020-04-30
WO2019064234A1 (en) 2019-04-04
AU2018343256A1 (en) 2020-04-02
HUE058102T2 (hu) 2022-07-28
EP3967301A1 (en) 2022-03-16
US10758497B2 (en) 2020-09-01
EP3967301B1 (en) 2024-06-19
US20230364028A1 (en) 2023-11-16
SMT202200093T1 (it) 2022-05-12
PT3687513T (pt) 2022-03-01
AU2018343256B2 (en) 2024-09-19
CA3300266A1 (en) 2026-03-02
JP2020535190A (ja) 2020-12-03

Similar Documents

Publication Publication Date Title
HUE058102T2 (hu) Fragilis X szindróma és autizmus kezelése kannabidiollal
IL293377B1 (en) Hsd17b13 variants and uses thereof
PL3673080T3 (pl) Oligomery antysensowne do leczenia stanów i chorób
DK3641819T3 (da) Anvendelse af cannabidiol i behandling af tuberøst sklerosekompleks
IL256673B (en) Vascularized in vitro perfusion devices, methods of fabricating, and applications thereof
SI3785717T1 (sl) Postopki za zdravljenje okužb s Coronaviridae
HUE056612T2 (hu) Hasnyálmirigyrák kezelésének eljárásai paclitaxel és gemcitabin segítségével
HUE037347T2 (hu) Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
HUE039997T2 (hu) Szulfamoilpirrolamid származékok és alkalmazásuk hepatitisz B kezelésére szolgáló gyógyszerekként
HUE040446T2 (hu) Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
FIC20260013I1 (fi) ikodekinsuliini ja semaglutidi
PL3362084T3 (pl) Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania
PL3044104T3 (pl) Ampułka do cieczy medycznej i sposób wytwarzania ampułki
PL3370540T3 (pl) Układ adsorpcji i sposób obsługi układu adsorpcji
FI20136131A7 (fi) Suoja, kaareva elementti ja suojan käyttö
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
PL4335517T3 (pl) Podawanie i dawkowanie diaminofenotiazyn
CL2016000392A1 (es) Análogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune
IL258997B (en) Honey-cannabinoid therapeutic composition
HUE054185T2 (hu) Eozinofilek és/vagy bazofilek megemelkedett szintjének kezelése
EP3546007A4 (en) CATHETER AND BALLOON CATHETER
EP3517161A4 (en) CATHETER AND BALLOON CATHETER
EP3558293C0 (en) SMALL MOLECULES INHIBITING SOX18 PROTEIN ACTIVITY IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS AND/OR LYMPHANGIOGENESIS
EP3601223A4 (en) ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULPHONIC ACID DERIVATIVES AND THEIR USES